GlassScriptPhysician profile
Fouad Darwish
NPI 1285698902
$8,807.64
in general payments reported to CMS, 2019-2025
28 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $249 · 2021: $6,439 · 2022: $543 · 2023: $593 · 2024: $593 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $49.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.87 |
| Education | $49.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,485.60 | 2020-2023 | Da Vinci Surgical System |
| Novo Nordisk INC | $424.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $292.71 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $223.32 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $203.49 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.43 | 2021-2024 | Xifaxan |
| Pfizer INC. | $120.99 | 2021-2025 | |
| Ardelyx, INC. | $98.42 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $92.30 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $89.42 | 2022-2023 | |
| Myovant Sciences INC. | $83.12 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.90 | 2022 | |
| Amgen INC. | $57.30 | 2023-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $45.83 | 2023 | Myrbetriq, Veozah |
| Kowa Pharmaceuticals America, INC. | $44.47 | 2023-2024 | Zoryve, Livalo, Seglentis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $35.16 | 2022 | |
| Nestle Healthcare Nutrition INC. | $31.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $28.96 | 2022-2024 | Farxiga |
| Phathom Pharmaceuticals, INC. | $25.56 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $24.86 | 2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $24.54 | 2022 | |
| Almatica Pharma LLC | $23.44 | 2022 | |
| Azurity Pharmaceuticals, INC. | $21.30 | 2024 | Edarbi |
| Bayer Healthcare Pharmaceuticals INC. | $18.11 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.59 | 2022 | |
| Radius Health, INC. | $15.21 | 2021 | |
| Amarin Pharma, INC. | $14.21 | 2021 | |
| Acerus Pharmaceuticals Corporation | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fouad Darwish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.